These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 12271179)

  • 21. Drug treatment for Alzheimer's disease: the way forward.
    Maidment I; Fox C; Livingston G; Katona C
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):6-8. PubMed ID: 16353163
    [No Abstract]   [Full Text] [Related]  

  • 22. Pressing issues in the dementias and dementia services.
    Holland M
    Hosp Med; 1999 Jul; 60(7):522-4. PubMed ID: 10605547
    [No Abstract]   [Full Text] [Related]  

  • 23. Variability in the prescription of cholinesterase inhibitors and memantine.
    Villar-Fernández I; Bjerrum L; Feja C; Rabanaque MJ
    Dement Geriatr Cogn Disord; 2009; 28(4):373-9. PubMed ID: 19887800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NICE proposes to withdraw Alzheimer's drugs from NHS.
    Kmietowicz Z
    BMJ; 2005 Mar; 330(7490):495. PubMed ID: 15746112
    [No Abstract]   [Full Text] [Related]  

  • 25. Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies.
    Gustavsson A; Van Der Putt R; Jönsson L; McShane R
    Int J Geriatr Psychiatry; 2009 Oct; 24(10):1072-8. PubMed ID: 19639600
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and cost-effectiveness of the pharmacological treatment of Alzheimer's disease and vascular dementia.
    Versijpt J
    J Alzheimers Dis; 2014; 42 Suppl 3():S19-25. PubMed ID: 25061049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reaching the population with dementia drugs: what are the challenges?
    Matthews FE; McKeith I; Bond J; Brayne C;
    Int J Geriatr Psychiatry; 2007 Jul; 22(7):627-31. PubMed ID: 17136710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease.
    Jönsson L
    Pharmacoeconomics; 2003; 21(14):1025-37. PubMed ID: 13129415
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of donepezil use in routine clinical practice on health care costs in patients with Alzheimer's disease and related dementias enrolled in a large medicare managed care plan: a case-control study.
    Lu S; Hill J; Fillit H
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):92-102. PubMed ID: 16129386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NICE recommends drugs for moderate Alzheimer's disease.
    Mayor S
    BMJ; 2006 Jan; 332(7535):195. PubMed ID: 16439382
    [No Abstract]   [Full Text] [Related]  

  • 31. [Therapeutic results: tacrine].
    Ventura M; Sternon J
    Rev Med Brux; 1997 Dec; 18(6):394-7. PubMed ID: 9481161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Comment on: Volz A, Monsch A.U., Zahno A., Wettstein A., Stähelin H.B., Grünig R.: What did Alzheimer disease cost Switzerland in 1998? A preliminary analysis].
    Marko P
    Praxis (Bern 1994); 2000 Jul; 89(27-28):1165-6. PubMed ID: 10959206
    [No Abstract]   [Full Text] [Related]  

  • 33. The economic consequences of Alzheimer's disease in the context of new drug developments.
    Knapp M; Wilkinson D; Wigglesworth R
    Int J Geriatr Psychiatry; 1998 Aug; 13(8):531-43. PubMed ID: 9733334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Viewpoint. Alzheimer's drugs debate.
    Manthorpe J; Iliffe S
    Ment Health Today; 2010 Dec-2011 Jan; ():31. PubMed ID: 21235054
    [No Abstract]   [Full Text] [Related]  

  • 35. Cholinesterase inhibitors for Alzheimer's disease: variations in clinical practice in the north-west of England.
    Purandare N; Swarbrick C; Fischer A; Burns A
    Int J Geriatr Psychiatry; 2006 Oct; 21(10):961-4. PubMed ID: 16927408
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alzheimer drugs: who benefits under NICE?
    Agnew T
    Nurs Older People; 2006 Dec; 18(11):7-8. PubMed ID: 17260590
    [No Abstract]   [Full Text] [Related]  

  • 37. Study notes huge costs associated with Alzheimer's disease.
    Levenson D
    Rep Med Guidel Outcomes Res; 2002 Feb; 13(4):7-9. PubMed ID: 12434776
    [No Abstract]   [Full Text] [Related]  

  • 38. The treatment of mild Alzheimer's disease post-NICE.
    Connelly PJ; Passmore AP; Lawlor BA
    Int J Geriatr Psychiatry; 2007 Dec; 22(12):1262-3. PubMed ID: 17503543
    [No Abstract]   [Full Text] [Related]  

  • 39. [Time-limited contribution concerning anti-dementia agents].
    Pedersen T; Hansen FR; Abelskov K
    Ugeskr Laeger; 2002 Oct; 164(43):5040; author reply 5040-1. PubMed ID: 12422402
    [No Abstract]   [Full Text] [Related]  

  • 40. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
    Fuh JL; Wang SJ
    Int J Geriatr Psychiatry; 2008 Jan; 23(1):73-8. PubMed ID: 17520661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.